argenx

"In the first four and a half years, my disease became my whole identity." 💬    For Alisa, living with myasthenia gravis (MG) meant every decision, plan, and little joy was shaped, or limited, by her condition. Today, advances in MG research and innovative treatment approaches are helping more people like Alisa rediscover what it means to live beyond their diagnosis.    At argenx, we’re advancing discovery together to redefine what’s possible for patients.     Explore more inspiring stories from our Dare to Care webinar series: https://bit.ly/43JiiMF   #DareToCare #AutoimmuneDiseases #MG #PatientVoices #TogetherWeDiscover 

At argenx, patients are at the center of everything we do. Each day we are motivated to pursue a better tomorrow for our patient community by listening, learning, and advancing together.     Learn more about our commitment to patient-centered progress: https://bit.ly/3LMbub3   #TogetherWeDiscover 

This #NationalFamilyCaregiversMonth, we’re celebrating the caregivers who give their time, strength, and compassion to their loved ones every day.    Allison and her husband, Eric, share how their journey with Multifocal Motor Neuropathy (MMN) has strengthened their connection and deepened their understanding of each other.   Their story reflects the resilience and partnership shared by the patient and caregiver community. Learn more: https://bit.ly/47JPFl0   #TogetherWeDiscover 

At argenx, quality is the foundation of every breakthrough.    It empowers safe and efficient innovation, ensuring that our work is translated into trusted solutions for patients.   When quality leads, progress becomes standard. Learn more: https://bit.ly/47Vvb7v   #TogetherWeDiscover

It’s official: ARGX-119 has received its name from the World Health Organization: adimanebart (ah-dee-MAH-neh-bart).   The name reflects both science and story. “Adi” honors the llama whose antibodies helped inspire its discovery, and “Ne” represents its connection to neural targets.   This milestone is an exciting step for our teams and reinforces our commitment to advancing research in neuromuscular diseases while keeping patients at the center of all we do.   #TogetherWeDiscover

Behind every diagnosis of an autoimmune disease are the people who stand beside the patients.    In our third episode of the Dare to Care webinar series, we’ll discuss navigating relationships while living with autoimmune conditions.    🔗 Sign up for Dare to Care updates: https://bit.ly/49IHZ3F   #DareToCare #AutoimmuneDiseases #MG #CIDP #PatientVoices #Caregivers #TogetherWeDiscover 

We’re honored to be ranked #7 on BioSpace’s 2026 Best Places to Work list 🎉   Thank you to our colleagues around the world for fostering a culture defined by curiosity, compassion, and innovation. Together, we continue to build an environment fueled by collaboration and a shared commitment to improving patients’ lives.    Learn more about what makes argenx a BioSpace Best Place to Work: https://bit.ly/47GjNfQ   #TogetherWeDiscover 

Building on a strong foundation, Q3 marked another period of accelerated momentum, as we advanced multiple clinical programs and prepared for a series of key data readouts in 2026.   This progress reflects our ongoing investment in innovation and commitment to Vision 2030 — our bold ambition to reach 50,000 patients worldwide by 2030, by expanding to additional indications and progressing multiple candidates through the advanced stages of clinical development.   Read the full Q3 2025 earnings report: https://bit.ly/4oft45s   #TogetherWeDiscover 

📢 Exciting week ahead! We’re sharing new data across generalized myasthenia gravis (gMG) patient communities at American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America, Inc. (MGFA) Scientific Session.     These findings further demonstrate our ambition to deliver transformational impact for people living with MG worldwide.    Learn more: https://bit.ly/47g5cJ6   #AANEMinSanFran #TogetherWeDiscover 

Neuromuscular diseases like MG, CIDP, and MMN each present unique challenges – and distinct opportunities for innovation.   We’re focused on raising awareness and advancing the science in these areas.   Learn how we’re driving innovation in neuromuscular diseases: https://bit.ly/4o3VfEk   #TogetherWeDiscover